TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Luteal phase defects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Neutrophil levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Achievement of LDL-C target
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to tumor recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in antral atrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Gastric mucosal injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: decreased symptom distress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: increased percent body fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean maximum effect for 'at the moment' Drug Liking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Drug Liking maximum effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean attitude score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: students' practice score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Quality of Life Scale (QLS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Social Functioning Inventory (SOFI)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Schizophrenia Positive and Negative Symptom Scale (PANSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5-year recurrence-free period
Endpoint domain: Mortality/survival
Primary endpoint: 5-year progression-free period
Endpoint domain: Mortality/survival
Primary endpoint: restoration of continence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: resolution of urgency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: normalization of micturition frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Frequency of ARDS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported abstinence at 1-week follow-up
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 24-hour quit attempt
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Drug abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical health profile
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mental health profile
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Composite of ischaemic or haemorrhagic stroke or systemic embolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alleviation of symptoms of depression, anxiety, and aggression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Plasma concentrations of cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Sufentanil requirements during maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of Contrast-Induced Nephropathy (CIN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: LOS function improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastro-oesophageal reflux episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: HF hospitalization rates
Endpoint domain: Mortality/survival
Primary endpoint: Mean alar base widening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean alar widening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean survival time (tumor recurrence)
Endpoint domain: Mortality/survival
Primary endpoint: occurrence of postoperative adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: overall adherence to medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left ventricular ejection fraction (LVEF) improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Worsening of depressive symptoms (5 or more points on CES-D)
Endpoint domain: Adverse events/effects
Primary endpoint: Gastric histological scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: apolipoprotein B concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Risk of cardioembolic stroke
Endpoint domain: Mortality/survival
Primary endpoint: Change in the proportion of thick hair (≥60 μm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in the proportion of vellus hair (<40 μm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Improvement in the appearance of baldness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: anaphylaxis preparedness score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anaphylaxis engagement score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duplex ultrasound peak systolic velocity increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Angiographic binary restenosis rate
Endpoint domain: Adverse events/effects
Primary endpoint: NIPS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 4 toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Serum CRP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Severe language problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients' global assessment of disease
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Soreness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of backache
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Knowledge of sex
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Attitude toward sex
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Parent‐efficacy on child sexuality education
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Success of surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Postoperative pain
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Acceptability score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: sICAM-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Gait speed gains
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cecal intubation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Need for assistance from a senior colleague
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: exclusive and predominant breastfeeding practice
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HAQ scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SF-36 physical component summary scores improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Symptoms of OCD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptoms of eating disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prevention of postoperative vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: X-ray consolidation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery of mobility ranges in knee and ankle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Transient hoarse voice recovery time
Endpoint domain: Adverse events/effects
Primary endpoint: Detection rate of flat/depressed lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction in BPI 24-hour average pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reductions in clinical symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reductions in disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of pregnancies with evidence of fetal cardiac activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Ongoing pregnancy rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Elimination half-life after intravenous bretylium tosylate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Elimination half-life after oral bretylium tosylate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Renal clearance after oral bretylium tosylate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Lung deposition of radioaerosol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: listening comprehension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PSA progression-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Confirmed Objective Response Rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: myocardial damage (measured as no increase in cTn-I)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: sum of R waves
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Medication-related problems (MRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total corneal thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative infection rate
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of biweekly angina attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Seattle Angina Questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ability to identify cancer stage
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: total scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stopwatch Time (ST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decline of depressive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACR50 improving rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in patient's outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Relative efficacy against rotavirus gastroenteritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction in medical visits for rotavirus gastroenteritis
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Crying behaviour during local anaesthetic administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of minor adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Gaining employment at 18-month follow-up
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Creatinine level increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Death or need for dialysis
Endpoint domain: Mortality/survival
Primary endpoint: Cataract surgery frequency
Endpoint domain: Adverse events/effects
Primary endpoint: Interobserver variation in optic disk parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum concentration of compound A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum concentration of compound B
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In-scaffold minimal lumen diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Neointimal strut coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Target lesion failure
Endpoint domain: Adverse events/effects
Primary endpoint: Triple hop performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Triple hop asymmetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CMJ performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically significant pocket haematoma
Endpoint domain: Adverse events/effects
Primary endpoint: overall physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dynamic lung volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: latency to persistent sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Plasma concentrations of total cholesterol, HDL, LDL, and triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Flow mediated vasodilation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: viral suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cell proliferation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cell apoptosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time to first morphine requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain score at 18 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improved quality of care
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: improvements in service delivery
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Physical and nutritional outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of non-aggressive prostate cancer
Endpoint domain: Mortality/survival
Primary endpoint: Risk of aggressive prostate cancer
Endpoint domain: Mortality/survival
Primary endpoint: Preoperative anxiety levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Potassemia levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Success rate of cannulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Success rate of sphincterotomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: activity hindrance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: commissure-commissure dimension at end-diastole
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: eccentricity at end-diastole
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: annular perimeter at end-systole
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: screening participation
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Endothelial vasomotor dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decline in bowel quality of life (QOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Ventilator-associated pneumonia (VAP)
Endpoint domain: Adverse events/effects
Primary endpoint: Oropharyngeal colonization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Complications (headache, vomiting, vision impairment, nausea, local swelling)
Endpoint domain: Adverse events/effects
Primary endpoint: Mean percent change in LS-BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean improvement in morning peak expiratory flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of days with no symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sensitivity rate of mPCR for detecting pathogenic bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Blood alcohol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Protective actions to keep group members safe
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Improvement in cognitive function (TMT, RAVLT, FAS scores)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: clinical scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC(last))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acute skin reactions grade
Endpoint domain: Adverse events/effects
Primary endpoint: Anthropometric measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in 24-h ambulatory BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: reduced intake of high energy dense snacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients' physical function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reductions in pain reports
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reductions in reports of anticipatory anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in bacterial numbers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Consumption rate of alcoholic beverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total inter-sip interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maintenance of aerobic exercise
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: peak fluticasone steady‐state plasma concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: area under the fluticasone plasma concentration‐time curve from 0‐6 hours (AUC0‐6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved clinical outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved functional outcomes
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: marked to complete improvement on calcipotriol‐treated sides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: repigmentation of hands and feet
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: LDL-C level reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: VABS‐II composite scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Inhibition of urinary leukotriene E₄
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Inhibition of blood leukotriene B₄
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Bone Mineral Density (BMD) T-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recurrence-free probability
Endpoint domain: Mortality/survival
Primary endpoint: rate of serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: BG/OC ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 8-meter walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean urgency urinary incontinence episodes per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Overactive Bladder Questionnaire Short Form symptom bother scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: urinary tract infections
Endpoint domain: Adverse events/effects
Primary endpoint: Symptomatic bronchospasm
Endpoint domain: Adverse events/effects
Primary endpoint: Forced expiratory volume in 1 sec (FEV1) return to within 10% of baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Levels of D-dimer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes